EFFECTS OF LOSARTAN AND BENAZEPRILON ABNORMAL CIRCADIAN BLOODPRESSURE RHYTHM AND TARGETORGAN DAMAGE IN SHRSP

REFERENCES

• Inada Y., Wada T., Ojima M., Sanada T., Shibouta Y., Kanagawa R., Ishimura Y., Fujisawa Y., Nishikawa K. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin. Exp. Hypertens. 1997; 19: 1079–1099
   PubMed Web of Science ®Google Scholar
• Millar-Craig M. W., Bishop C. N., Raftery E. B. Circadian variation of blood–pressure. Lancet 1978; 1: 795–797
   PubMed Web of Science ®Google Scholar
• Pickering T. G. The clinical significance of diurnal blood pressure variations, dippers and nondippers. Circulation 1990; 81: 700–702
   PubMed Web of Science ®Google Scholar
• Suzuki Y., Kuwajima I., Kanemaru A., Shimasawa T., Hoshino S., Sakai M., Matsushita S., Ueda K., Kuramoto K. The cardiac functional reserve in elderly hypertensive patients with abnormal diurnal change in blood pressure. J. Hypertens. 1992; 10: 173–179
   PubMed Web of Science ®Google Scholar
• Kario K., Matsuo T., Kobayashi H., Imiya M., Matsuo M., Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients, Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130–135
   PubMed Web of Science ®Google Scholar
• Redon J., Miralles A., Liao Y., Lozano J. V., Pascual J. M., Cooper R. S. Circadian variability and microalbuminuria in essential hypertension. J. Hypertens. 1994; 12: 947–954
   PubMed Web of Science ®Google Scholar
• Lemmer B., Mattes A., Manfred B., Ganten D. Circadian blood pressure variation in transgenic hypertensive rats. Hypertension 1993; 22: 97–101
   PubMed Web of Science ®Google Scholar
• Ogata J., Fujishima M., Tamaki K., Nakatomi Y., Ishitsuka T., Omae T. Stroke-prone spontaneously hypertensive rats as an experimental model of malignant hypertension. Virchows Arch. 1982; 394: 185–194
   PubMed Web of Science ®Google Scholar
• Kim S., Ohta K., Hamaguchi A., Omura T., Yukimura T., Miura K., Inada Y., Wada T., Ishimura Y., Chatani F., Iwao H. Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int. 1994; 46: 1346–1358
   PubMed Web of Science ®Google Scholar
• Feron O., Salomon S., Godfraind T. Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats. Br. J. Pharmacol. 1996; 118: 659–664
   PubMed Web of Science ®Google Scholar
• Shimamura T., Nakajima M., Iwasaki T., Hayasaki Y., Yonetani Y., Iwaki K. Analysis of circadian blood pressure variation and target organ damage in stroke-prone spontaneously hypertensive rats. J. Hypertens. 1999; 17: 211–220
   PubMed Web of Science ®Google Scholar
• Trachtman H., Futterweit S., Maesaka J., Ma C., Valderrama E., Fuchs A., Tarectecan A. A., Rao P. S., Sturman J. A., Boles T. H., Fu M. X., Baynes A. J. Taurine ameliorates chronic streptozocin-induced diabetic nephropathy in rats. Am. J. Physiol. 1995; 269: F429–F438
   PubMed Web of Science ®Google Scholar
• Salzmann J. L., Michel J. B., Bruneval P., Nlom M. O., Barres D. R., Camilleri J. P. Automated image analysis of myocardial collagen pattern in pressure and volume overload in rat cardiac hypertrophy. Analytic Quant. Cytol. Histol. 1986; 8: 326–332
   PubMed Web of Science ®Google Scholar
• Clozel J. P., Hefti F. Cilazapril prevents the development of cardiac hypertrophy and the decrease of coronary vascular reserve in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 1988; 11: 568–572
   PubMed Web of Science ®Google Scholar
• Pfeffer J. M., Pfeffer M. A., Mirsky I., Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rats. Proc. Natl. Acad. Sci. USA 1989; 79: 3310–3314
   Google Scholar
• Meyer T. W., Anderson S., Rennke H. G., Brenner B. M. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int. 1987; 31: 752–759
   PubMed Web of Science ®Google Scholar
• Xie M. H., Liu F. Y., Wong P. C., Timmermann P. B., Cogan M. G. Proximal nephron and renal effects of DuP753, a non-peptide angiotensin II receptor antagonist. Kidney Int. 1990; 38: 473–479
   PubMed Web of Science ®Google Scholar
• Hamaguchi A., Kim S., Wanibuchi H., Iwao H. Angiotensin II and calcium channel blockers prevent glomerular phenotypic changes in remnant kidney model. J. Am. Soc. Nephrol. 1996; 7: 687–693
   PubMed Web of Science ®Google Scholar
• Burdmann E. A., Andoh T. F., Nast C. C., Evan A., Connors B. A., Coffman T. M., Lindsley J., Bennett W. M. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am. J. Physiol. 1995; 269: F491–F499
   PubMed Web of Science ®Google Scholar
• Toblli J. E., Stella I., Cavanagh E. de, Angerosa M., Inserra F., Ferder L. Enalapril prevents tubulointerstitial lesions by hyperoxaluria. Hypertension 1999; 33: 225–231
   PubMed Web of Science ®Google Scholar
• Imai Y., Abe K., Sasaki S., Minami N., Nihei M., Munakata M., Murakami O., Matsue K., Sekino H., Miura Y., Yoshinaga K. Altered circadian blood pressure rhythm in patients with Cushing's syndrome. Hypertension 1988; 12: 11–19
   PubMed Web of Science ®Google Scholar
• Tanaka T., Natsume T., Shibata H., Nozawa K., Kojima S., Tsuchiya M., Ashida T., Ikeda M. Circadian rhythm of blood pressure in primary aldosteronism and renovascular hypertension, analysis by cosinor method. Jpn. Circ J. 1983; 47: 788–794
   PubMedGoogle Scholar
• Campbell D. J., Lawrence A. C., Towrie A., Kladis A., Valentijn A. J. Effect of converting enzyme inhibitor, perindopril, on angiotensin peptides in plasma and kidney of the rat. Genetic hypertension, J. Sassard, 1992; 218:257–259, Paris, INSERM/John Libbey Eurotext
   Google Scholar
• Ura N., Carretero O. A., Erdos E. G. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int. 1987; 32: 507–513
   PubMed Web of Science ®Google Scholar
• Buckenburg B., Schnell C., Baum H. P., Cumin F., Wood J. Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hypertension 1991; 18: 278–288
   PubMed Web of Science ®Google Scholar
• Bahnson T. D., Kim N. N., Dubin A. E., Gallagher A. M. Bradykinin decreases mRNA levels for fibronectin and collagen via activation of intracellular Ca2+ mobilization and Ca2+ entry in cardiac fibroblasts. Circulation 1996; 94: I–713. Abstract
   Google Scholar
• Ozono R., Wang Z. Q., Moore A. F., Inagami T., Siragy H. M., Carey R. M. Expression of the subtype-2 angiotensin (AT2) receptor protein in rat kidney. Hypertension 1997; 30: 1238–1246
   PubMed Web of Science ®Google Scholar
• Goto M., Mukoyama M., Suga S., Matsumoto T., Nakagawa M., Ishibashi R., Kasahara M., Sugawara A., Tanaka I., Nakao K. Growth-dependent induction of angiotensin II type 2 receptor in rat mesangial cells. Hypertension 1997; 30: 358–362
   PubMed Web of Science ®Google Scholar
• Ma J., Nishimura H., Fogo A., Kon V., Inagami T., Ishikawa I. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int. 1998; 53: 937–944
   PubMed Web of Science ®Google Scholar